CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? [Yahoo! Finance]
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: Yahoo! Finance
still translate into meaningful revenue opportunities thanks to premium pricing, regulatory incentives, and limited competition. Companies operating in this niche often benefit from clearer clinical endpoints and faster regulatory pathways, which can accelerate time to market compared with traditional mass-market drugs. CorMedix's lead product, DefenCath (Taurolidine + Heparin), received FDA approval in late 2023 as the first and only antimicrobial catheter lock solution available in the United States. It is indicated for reducing catheter-related bloodstream infections in adult patients with kidney failure undergoing chronic hemodialysis through a central venous catheter. On the other hand, Mirum Pharmaceuticals' lead product, Livmarli (maralixibat), is approved for the treatment of cholestatic pruritus (intense itching) in patients with Alagille syndrome (ALGS) worldwide. The drug, an orally administered IBAT inhibitor, is also approved for treating cholestatic pruritus in patie
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 [Yahoo! Finance]Yahoo! Finance
- CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026GlobeNewswire
- CorMedix (NASDAQ:CRMD) had its price target lowered by analysts at HC Wainwright from $18.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
- CorMedix (NASDAQ:CRMD) was given a new $13.00 price target on by analysts at Royal Bank Of Canada.MarketBeat
- CorMedix: The Post-TDAPA Hangover Arrived Early (Rating Downgrade) [Seeking Alpha]Seeking Alpha
CRMD
Earnings
- 11/12/25 - Beat
CRMD
Sec Filings
- 1/27/26 - Form 4
- 1/27/26 - Form 4
- 1/27/26 - Form 4
- CRMD's page on the SEC website